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Streszczenie
Wstęp: U kobiet po menopauzie częściej występuje zespół
metaboliczny (ZM) i choroby układu krążenia. Adiponek-
tyna i leptyna produkowane przez tkankę tłuszczową od-
grywają rolę w patogenezie ZM.
Cel pracy: Ocena wpływu menopauzy na powiązania mię-
dzy adiponektyną oraz leptyną i różnymi czynnikami ry-
zyka.
Materiał i metody: Do badania włączono 56 kobiet po me-
nopauzie i 75 młodych kobiet. Oceniano: ciśnienie tętnicze,
wskaźnik masy ciała (BMI, body mass index), obwód w talii,
WHR, stężenie triglicerydów (TG), cholesterolu frakcji HDL
(cHDL), stężenie glukozy na czczo i w teście obciążenia glu-
kozą 75 g. Badane kobiety podzielono na podgrupy w za-
leżności od liczby stwierdzonych czynników ryzyka. Przy
obecności co najmniej 3 czynników rozpoznawano zespół
metaboliczny. Stężenie adiponektyny i leptyny oceniano
metodą RIA.
Wyniki: Stężenie adiponektyny malało wraz ze wzrostem
liczby czynników ryzyka w grupie przed- i pomenopauzal-
nej. W porównaniu do młodych kobiet z ZM, u kobiet po
menopauzie i z ZM stwierdzono istotnie niższe stężenia adi-
ponektyny. W przeciwieństwie do przedmenopauzalnych
kobiet, w grupie pomenopauzalnej wraz z rosnącą liczbą
czynników ryzyka obserwowano wzrost stężenia leptyny.
Porównując młode kobiety z ZM i kobiety pomenopauzal-
ne z ZM, obserwowano wyższe stężenia leptyny w tej ostat-
niej podgrupie. Stwierdzono zależności między leptyną
i różnymi składowymi ZM, zwłaszcza u kobiet po meno-
pauzie. W analizie wieloczynnikowej, adiponektyna i lep-
tyna stanowiły niezależne czynniki powiązane z ZM.
Wnioski: Potwierdzono istotną rolę patofizjologiczną
adiponektyny w rozwoju ZM. Leptyna jest powiązana
z różnymi czynnikami ryzyka, ale wydaje się, że odgry-
wa ona rolę w patogenezie ZM jedynie u pomenopau-
zalnych kobiet.
(Endokrynol Pol 2006; 1 (57): 15–22)
Słowa kluczowe: adiponektyna, leptyna, menopauza, zespół
metaboliczny
Dr med. Lucyna Siemińska
Katedra Patofizjologii i Endokrynologii, ŚAM
plac Traugutta 2, 41–800 Zabrze
e-mail: lusiem@poczta.onet.pl

16
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 57; Numer/Number 1/2006
ISSN 0423–104X
Introduction
It is well known that there is a higher prevalence of car-
diovascular risk factors and metabolic syndrome (MS)
in postmenopausal women [1]. This is caused by incre-
ased obesity, redistribution of the fat mass and insulin
resistance. It has been shown that an excess of fat mass
and insulin resistance are two independent factors that
contribute to an unfavourable metabolic profile in wo-
men after the menopause [2]. The occurrence of both
these factors simultaneously creates the conditions that
are most detrimental to the metabolic profile [2].
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Abstract
Introduction: It is well known that there is a higher preva-
lence of cardiovascular risk factors and metabolic syndro-
me (MS) in postmenopausal women. Recently it has beco-
me evident that adiponectin and leptin secreted by adipose
tissue may be involved in the pathophysiology of MS.
The aim of the study: was to assess the effects of the meno-
pause on the relationships between adiponectin and leptin
and different cardiovascular and metabolic risk factors.
Materials and methods: A total of 56 postmenopausal wo-
men and 75 premenopausal subjects were enrolled in this
study. We measured blood pressure, BMI, waist circumfe-
rence and WHR, triglycerides (TG), high density lipoprote-
in cholesterol (cHDL) levels and fasting glucose and applied
the oral glucose tolerance test (OGTT). Women were cate-
gorised as having 0, 1, 2, 3 or more risk factors. The presen-
ce of at least 3 abnormalities was defined as MS. Serum was
assayed for adiponectin and leptin by the radioimmunoas-
say (RIA) method.
 Results: A decline in adiponectin was related to an incre-
ased number of MS variables in postmenopausal and pre-
menopausal women. Postmenopausal women with MS had
significantly lower adiponectin concentrations than preme-
nopausal women with MS. Serum adiponectin concentra-
tions were inversely correlated to leptin in postmenopau-
sal women. In premenopausal women no clear relationships
were found between serum leptin and the number of me-
tabolic disturbances. In contrast to young women, postme-
nopausal women showed an increase in leptin secretion
with a growing number of MS elements. Compared to pre-
menopausal women with MS, postmenopausal women with
MS had higher levels of leptin. We found associations be-
tween leptin and different risk factors, mainly in the post-
menopausal group. When the presence of MS was used as
a dependent variable (yes/no) and adiponectin, leptin and
menopause status as independent factors, adiponectin and
leptin remained significant variables related to MS.
Conclusion: The significant role of adiponectin in the pa-
thophysiology of MS in premenopausal and postmenopau-
sal women is confirmed in this study. Leptin is correlated
with several MS components but this adipocytokine appe-
ars to play a role only in postmenopausal women.
(Pol J Endocrinol 2006; 1 (57): 15–22)
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The exact mechanisms mediating the relationship
between the accumulation of visceral fat after the me-
nopause and metabolic disturbances remain unknown.
Recently it has become evident that the adiponectin
and leptin secreted by adipose tissue and free fatty
acids (FFA) may be involved in the pathophysiology
of MS [3].
Previous research has shown a relationship betwe-
en obesity and decreasing adiponectin and increased
leptin production [4–8]. It is still unclear whether the
menopause influences the synthesis of adipocytokines.
Only limited data are available with regard to this matter
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4. BMI ≥ 25; 5. (a) impaired fasting glucose (IFG) (fa-
sting glucose ≥ 6,1 mmol/l and < 7.0 mmol/l) or (b) im-
paired glucose tolerance (IGT) (glucose ≥ 7.8 mmol/l
and < 11.1 mmol/l in 120 minutes after OGTT); 6. (a)
waist circumference (ATP III takes 88 cm as the upper
limit) and (b) WHR (the WHO has established the up-
per limit of the WHR as 0.85). These were evaluated in
view of the fact that abdominal obesity shows a high
degree of correlation with metabolic risk factors. Wo-
men were then categorised as having 0, 1, 2, 3 or more
of the above 6 metabolic disturbances.
Serum adiponectin and leptin levels were determi-
ned by radioimmunoassay using commercial kits (Lin-
co Research, St. Charles, MO).
The study was approved by the Ethics Committee
of the Silesian Medical University (Katowice, Poland).
Statistical analysis was performed using the Statisti-
ca 7.1 package by StatSoft Inc., Tulsa, OK. The postme-
nopausal and premenopausal women were tested se-
parately. Concentrations are presented as means ± SD
for normally distributed data or medians plus (25th; 75th)
percentiles for abnormal distribution in the Shapiro-
Wilks W test. For comparisons between groups the
t test or the Mann-Whitney U test were used. Spearman’s
correlation coefficients were used to estimate linear re-
lationships between variables. Comparisons of values
in multiple groups were tested using one-way ANO-
VA. Fisher’s exact probability test was used to investi-
gate the proportion of MS variables in the postmeno-
pausal women to those in the premenopausal women.
Multiple regression analysis was performed in different
models as described in the “Results” section. It was as-
sumed that the difference was significant at p < 0.05.
Results
Of the 131 women studied, 56 were in postmenopausal
and 75 were in the premenopausal group. Table I cha-
racterises the subjects. Groups were differentiated with
regard to age, BMI, WHR and waist circumferences.
Previous studies have shown that adiponectin and lep-
tin concentrations depend on BMI, WHR and waist cir-
cumference and are related to MS [3–9]; therefore, we
analysed the groups separately according to the num-
ber of MS components. The postmenopausal and pre-
menopausal women were divided into four subgroups
with 0, 1, 2 and 3 or more abnormalities respectively.
The criteria for the anthropometric measurements, li-
pid and carboxyhydrate metabolism, as well as the va-
lues for blood pressure, are described in “Material and
methods”. In this study MS was defined the presence
of at least three abnormalities.
The prevalence of MS was 9% in premenopausal
women and 30% in postmenopausal women. Most
and results vary. Some studies have shown decreased
adiponectin and increased leptin levels in postmeno-
pausal women [9, 10], while others have not [11, 12]. In
our previous study we compared overweight postme-
nopausal and premenopausal women matched for body
mass index (BMI) and failed to find any difference in
adiponectin levels between the groups [13]. However,
some reports have described elevated levels of adipo-
nectin [14] and a decreased concentration of leptin in
women after the menopause [7]. Discrepancies can be
attributed to differences in the body composition of the
subjects. Therefore, in order to reduce any bias due to
confounding variables, we analysed postmenopausal
women in relation to premenopausal women according
to the number of MS components.
The objective of the present study was to assess the
effects of the menopause on the relationships between
adiponectin and leptin and various cardiovascular and
metabolic risk factors, to determine whether there is an
independent relationship between adiponectin, leptin
and MS and to assess whether the number of MS com-
ponents is associated with adiponectin and leptin con-
centrations in postmenopausal and premenopausal
women.
Materials and methods
We studied 56 postmenopausal (age 48–64) and 75 pre-
menopausal women (age 21–40 years) recruited from
women visiting the endocrinological and gynaecologi-
cal clinics for routine check-up. The premenopausal
women had regular menstrual cycles and none had re-
cognised diabetes, ischaemic heart disease or any other
chronic disease. Postmenopausal status was defined by
amenorrhoea for at least 1 year. The exclusion criteria
were the same as for young women.
MS is characterised by a clustering of the following
abnormalities: abdominal obesity, insulin resistance,
impaired glucose tolerance, dyslipidaemia, and hyper-
tension. Since WHO, the American Association of Cli-
nical Endocrinologists (AACE) and the National Chole-
sterol Education Program’s Adult Treatment Panel III
(ATP III) have recommended slightly differing criteria
for diagnosis of MS [15], for the purposes of this study
we have taken into account parameters that include parts
of the lists of each of these organisations. For each wo-
man we evaluated the following risk factors: blood pres-
sure, BMI, waist circumference and waist-to-hip ratio
(WHR), triglycerides (TG), cHDL levels, fasting glucose
and the results of the oral glucose tolerance test (OGTT).
Following the WHO, ATP III and AACE guidelines, we
considered the following cut-off limits for MS abnor-
malities: 1. TG > 1.7 mmol/l; 2. cHDL < 1.29 mmol/l;
3. hypertension if blood pressure ≥ 130/85 mm Hg;
18
Serum adiponectin and leptin levels in metabolic syndrome Lucyna Siemińska i wsp.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
premenopausal women (71%) had a healthy metabolic
profile (0 features). Most postmenopausal women were
characterised by 1 to 2 components of MS (59%).
For both groups lower serum adiponectin levels
were present, as the greater number of MS components
were clustered (Fig. 1). However, adiponectin concen-
tration in the postmenopausal women with MS was si-
gnificantly lower than in young women with MS. No
differences in serum adiponectin were found between
the postmenopausal and the younger women when
these were compared to women with no disturbances.
Similar results were obtained for subjects with one or
two abnormalities.
There was a stepwise increase in serum leptin as the
number of MS elements increased in postmenopausal
women (Fig. 2). Postmenopausal women with MS were
found to have higher levels of leptin when compared
to younger women with MS.
Simple correlations and multiple regression
analyses
When analysis was conducted for all postmenopausal
women, serum adiponectin correlated with all risk fac-
tors: BMI (p < 0.001), WHR (p < 0.001), waist circumfe-
rence (p < 0.001), TG (p < 0.001) and cHDL (p < 0.001).
We observed negative associations between adiponec-
tin and leptin in postmenopausal women (p < 0.01).
Figure 1. Dependence of serum adiponectin on the numbers of
risk factors in premenopausal and postmenopausal women. The
columns indicate the median, with percentyles (75th, 25th) in
brackets; * p < 0.001 premenopausal vs. postmenopausal women
Rycina 1. Zależność stężenia adiponektyny od liczby czynników
ryzyka u kobiet przed i po menopauzie. Słupki przedstawiają
mediany; w nawiasach umieszczono percentyle (75, 25); *p < 0,001
u kobiet przed vs. po menopauzie
Table I
Physical and clinical characteristics of the postmenopausal and premenopausal women studied
Tabela I
Charakterystyka grup badanych kobiet przed i po menopauzie
Variable Postmenopausal women, n = 56 Premenopausal women, n = 75 p
Age [years] 53.9 ± 3.2 28.2 ±  4.1 < 0.001
BMI [kg/m2] 27.2 ± 3.1 23.3 ± 2.0 < 0.001
WHR 0.84 ± 0.03 0.76 ± 0.05 < 0.001
Waist circumference [cm] 89.0 [84; 94.5] 78.0 [76.0; 85.0] < 0.001
TG [mmol/l] 1.8 ± 0.40 1.44 ± 0.21 < 0.001
CHDL [mmol/l] 1.4 ± 0.15 1.57 ± 0.49 < 0.001
Hypertension 17 [30%] 5 [7%] < 0.001
Disturbances of glucose metabolism 31 [55%] 10 [13%] < 0.001
Adiponectin [mg/ml] 15.1 [9.8; 17.4] 17.4 [14.5; 21.0] < 0.001
Leptin [ng/ml] 14.7 [10.7; 17.3] 11.0 [8.3; 12.0] < 0.001
0 factors of MS 6 [11%] 53 [71%] < 0.001
1 factor of MS 15 [27%] 9 [12%] < 0.05
2 factors of MS 18 [32%] 6 [8%] < 0.001
≥ 3 factors of MS 17 [30%] 7 [9%] < 0.001
Skewed data are given as median plus [25th; 75th] percentiles. Normally distributed data are given as mean ± SD. The significance tests used are the
Mann-Whitney U test for the variables that are not normally distributed and the unpaired t-test for the normally distributed variables. Fisher’s exact
probability test was used to compare disparities between the groups in the frequency of the markers of metabolic syndrome. Disturbances of glucose
metabolism include IFG or IGT
The stepwise regression analysis performed on the post-
menopausal group with MS abnormalities as indepen-
dent variables showed that WHR, leptin, disturbances
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cantly associated with BMI (p < 0.01), WHR (p < 0.001),
waist circumference (p < 0.001) and TG (p < 0.001). Ste-
pwise regression analysis using the same independent
variables as for the postmenopausal group showed
that waist circumference, TG, IFG/IGT and hypertension
emerge as independent predictors of adiponectin
concentration in premenopausal women (R2 = 0.47,
p < 0.001, Tab. II).
In postmenopausal women leptin was positively
correlated with BMI (p < 0.001), WHR (p < 0.001), wa-
ist circumference (p < 0.001), TG (p < 0.001), cHDL
(p < 0.001) and adiponectin (p < 0.01). In premenopau-
sal women leptin was associated with BMI (p < 0.01),
waist circumference (p < 0.01) and WHR (p < 0.01).
In this group no association was demonstrated betwe-
en leptin and lipid or glucose disturbances and no re-
lationship was found between serum leptin and the
number of metabolic disturbances (Fig. 2). In multiple
stepwise regression analysis performed in the post-
menopausal group BMI and adiponectin remained in-
dependent predictors for leptin (R2 = 0.66, p < 0.001,
Tab. II). The following variables were entered into the
model: BMI, WHR, waist circumference, TG, cHDL, adi-
ponectin, hypertension (yes/no) and IFG/IGT (yes/no).
In contrast, in the premenopausal group BMI and
WHR were related independently to leptin concentration
(R2 = 0.39; p < 0.01).
When the presence of MS was used as a dependent
variable (yes/no), and adiponectin, leptin, and meno-
pause status as independent factors, adiponectin and
Figure 2. Dependence of serum leptin on the numbers of risk factors
in premenopausal and postmenopausal women. The columns
indicate the median, with percentyles (75th, 25th) in brackets;
* p < 0.001 premenopausal vs. postmenopausal women
 Rycina 2. Zależność stężenia leptyny od liczby czynników ryzyka
u kobiet przed i po menopauzie. Słupki przedstawiają mediany;
w nawiasach umieszczono percentyle (75, 25); *p < 0,001 u kobiet
przed vs. po menopauzie
Table II
Multiple linear regression analysis using serum adiponectin or leptin as dependent parameters. The analysis was performed
separately for premenopausal and postmenopausal subjects
Tabela II
Stężenia adiponektyny lub leptyny jako parametry zależne w analizie modelu liniowej regresji wielorakiej. Osobno rozpatry-
wano wyniki badań w grupach przed i po menopauzie
Adiponectin as a dependent variable Leptin as a dependent variable
Premenopausal women Postmenopausal women Premenopausal women Postmenopausal women
Independent Regression p Regression p Regression p Regression p
parameter coefficient beta coefficient beta coefficient beta coefficient beta
BMI –0.03 NS –0.1 NS 0.37 < 0.001 0.46 0.001
WHR –0.12 0.NS –0.20 0.04 0.35 0.001 0.16 NS
Waist circumference –0.22 0.04 –0.14 NS 0.16 NS 0.16 NS
TG –0.31 0.001 –0.13 NS 0.19 NS 0.17 NS
CHDL 0.11 NS 0.01 NS 0.04 NS 0.01 NS
Leptin –0.02 NS –0.27 0.01
Adiponectin 0.03 NS –0.32 < 0.01
Disturbances of glucose –0.32 0.001 –0.24 < 0.001 0.13 NS 0.11 NS
metabolism (yes/no)
Hypertension (yes/no) –0.29 <0.01 –0,20 < 0.01 –0.15 NS –0.04 NS
                     R2 = 0.47, p < 0.001        R2 = 0.71, p < 0.001              R2 = 0.39, p < 0.01          R2 = 0.66, p < 0.001
Disturbances of glucose metabolism include IFG or IGT
in glucose metabolism and the presence of hyperten-
sion were independent predictors for serum adiponec-
tin (R2 = 0.71, p < 0.001, Tab. II).
In the premenopausal women, linear regression ana-
lysis showed that serum adiponectin levels were signifi-
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leptin remained significant and independent variables
related to MS. Table III presents a summary of the mo-
del (R2 = 0.54, p < 0.001).
Discussion
The menopause is associated with obesity and with an
increased risk of MS developing [1, 16]. In our study
the prevalence of MS in postmenopausal women was
indeed found to be high.
The aetiology of postmenopausal obesity is not ful-
ly known but it has become apparent that decreased
physical activity, a reduced resting metabolic rate, an
increase in fat intake and a decrease in fat oxidation all
play a role [17]. The accumulation of visceral fat in post-
menopausal women suggests that hypo-oestrogenism
arising from ovarian failure may be responsible for fat
redistribution. Many investigators have demonstrated
that visceral fat significantly correlates with insulin re-
sistance [18]. However, the hypothesis that increased
FFA release into the portal vein leads to hepatic insulin
resistance has recently been questioned [19]. Some stu-
dies have demonstrated a strong correlation between
insulin sensitivity and subcutaneous fat mass [20] and
between both visceral and subcutaneous fat and insu-
lin resistance [21]. It is possible that subcutaneous trun-
cal fat influences peripheral insulin sensitivity by rele-
asing large amounts of FFA to the systemic circulation.
In contrast, leg fat mass seems to be a significant pro-
tective factor, associated with a more favourable meta-
bolic profile [22]. Low subcutaneous thigh fat is consi-
dered to be a risk factor for carboxyhydrate and lipid
disturbances [23].
Adipose tissue produces various amounts of adipo-
nectin and leptin at different body sites. Adiponectin is
derived from visceral fat mass, while leptin is secreted
mainly by subcutaneous adipose tissue [6]. Serum adi-
ponectin is decreased in abdominal obesity [3, 4], altho-
ugh serum leptin levels are related to the subcutaneous
fat of the lower leg [24]. The proportions of leptin rele-
ase from visceral and subcutaneous compartments
change after the menopause and increased secretion
from visceral fat is observed [7]. Adipocytokines affect
carbohydrate and lipid metabolism and, therefore, play
a role in the pathogenesis of hypertension, atheroscle-
rosis and diabetes [3–5, 25]. This hormone appears to
have an impact on glucose and lipid metabolism in ske-
letal muscle, liver and in adipose tissue and has an anti-
inflammatory effect on the vascular wall. Adiponectin
inhibits monocyte adhesion to endothelial cells, sup-
presses macrophage-to-foam cell transformation and
attenuates proliferation of smooth muscle cells [26]. Sin-
ce it has become evident that inhibition of adiponectin
production occurs during the development of obesity,
hypoadiponectinaemia appears to be a link between
obesity, insulin resistance and vascular disease. In our
study a decline in adiponectin was related to an incre-
ased number of MS variables. These results are in agre-
ement with previous reports [27]. Our results also de-
monstrate that postmenopausal women with MS have
significantly lower adiponectin concentrations than
premenopausal women with MS. This finding sugge-
sts that there is another factor that influences the as-
sociations between MS and adiponectin levels in post-
menopausal women. In this study we demonstrated
that serum adiponectin concentrations were inversely
correlated to leptin in postmenopausal women. These
associations remained statistically significant after mul-
tiple stepwise regression analysis. The mechanism un-
derlying the observed associations is unknown. The ob-
servation has recently been made that hyperleptinaemia
and hypoadiponectinaemia work together to accelerate
atherosclerosis in obese subjects [28] and Satoh et al. sug-
gest that the high leptin-to-adiponectin ratio is a marker
of accelerated atherogenesis [29]. Recently the connec-
tions between lipoprotein lipase and adiponectin as well
as leptin have been actively investigated; examples are
studies by von Eynatten et al. [30] and Maingrette et al.
[31]. Unfortunately, the direct relationship between adi-
ponectin and leptin with respect to lipoprotein lipase
remains uncertain. The other possible mechanism linking
low adiponectin and high leptin involves the increased
risk of insulin resistance after the menopause [32]. Adi-
ponectin has been shown to be suppressed in states of
insulin resistance [4, 5]. Leptin also contributes to the
deterioration of insulin sensitivity [6–8]. Furthermo-
re, the postmenopausal status is characterised by hi-
gher TNF-alpha levels [33] which reduce adiponectin
levels. Positive associations between TNF-alpha and
leptin have also been reported [34]. Unfortunately,
these parameters were not measured in the present stu-
dy and this hypothesis needs to be confirmed.
Table III
Stepwise regression analysis for independent predictors of the
presence of MS in premenopausal and postmenopausal
women taken together
Tabela III
Niezależne czynniki rokownicze wystąpienia zespołu meta-
bolicznego w analizie modelu regresji krokowej rozpatrywa-
ne łącznie u kobiet przed i po menopauzie
Independent parameter Regression coefficient beta p
Adiponectin –0.53 0.001
Leptin 0.29 0.001
Menopause yes/no –0.2 0.001
                                R2 = 0.54, p < 0.001
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Leptin has been shown to be linked to adiposity and
insulin resistance. Leyva et al. [8] have demonstrated
the relationships between hyperleptinaemia and obe-
sity, increased pressure, insulin resistance, hyperinsu-
linaemia and hypertriglyceridaemia. The effect of lep-
tin on the development of MS is not fully understood.
The leptin receptor has been identified on endothelial
cells and leptin has been shown to promote atheroge-
nic processes [35]. Elevated levels of leptin induce fatty
acid oxidation, which plays a role in the progression of
atherosclerosis [36]. Moreover, leptin enhances lipopro-
tein lipase secretion from macrophages contributing to
monocyte adhesion to the endothelium and to the trans-
formation of macrophages into foam cells [29]. In many
studies leptin has been shown to be a marker of coro-
nary events. Leptin increases sympathetic nervous ac-
tivity and the administration of leptin in animal mo-
dels causes a rise in blood pressure.
In our study serum leptin in premenopausal women
correlated with BMI and WHR but no association was
found with lipid, glucose abnormalities and adiponec-
tin. No clear relationships were found between serum
leptin and the number of metabolic disturbances. In
contrast to young women, postmenopausal women
showed an increase in leptin secretion with a growing
number of MS elements and in stepwise regression ana-
lysis leptin remained an independent factor related to
MS. A possible reason for the difference between pre-
menopausal and postmenopausal women is that leptin
secretion after the menopause is due to increased vi-
sceral fat [7]. This may contribute to the metabolic dete-
rioration that occurs in women during this period. In
our study the median concentration of leptin was si-
gnificantly higher in postmenopausal women when
compared with the premenopausal group.
In conclusion, the significant role of adiponectin in
the pathophysiology of MS in premenopausal and post-
menopausal women was confirmed in this study. Lep-
tin is correlated with several MS components but this
adipocytokine only appears to play a role in postmeno-
pausal women.
The main factor determining the occurrence of MS
in women is a depressed level of adiponectin. Howe-
ver, a high degree of leptin concentration also emerges
as a factor contributing to the pathophysiology of MS.
The precise role of adiponectin and leptin is probably
complex and future studies in this matter are needed.
This study was supported by a grant from the State
Committee for Scientific Research (3 P05E 161 23).
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